See more : Acri Capital Acquisition Corporation (ACAC) Income Statement Analysis – Financial Results
Complete financial analysis of TheraVet SA (ALVET.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TheraVet SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Sunda Energy Plc (SNDA.L) Income Statement Analysis – Financial Results
- Smart Sand, Inc. (SND) Income Statement Analysis – Financial Results
- GuangDong SongYang Recycle Resources CO.,LTD (603863.SS) Income Statement Analysis – Financial Results
- Metals Acquisition Corp (MTAL-WT) Income Statement Analysis – Financial Results
- Windsor Machines Limited (WINDMACHIN.NS) Income Statement Analysis – Financial Results
TheraVet SA (ALVET.PA)
About TheraVet SA
TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET for osseointegration and bone remodelling; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid with anti-inflammatory properties that promotes the effect of active components, as well as acts as a cell colonization supporting tissue regeneration. The company was incorporated in 2017 and is headquartered in Jumet, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.08M | 1.60M | 1.94M | 987.81K | 780.64K |
| Cost of Revenue | 1.61M | 2.59M | 2.55M | 1.10M | 780.16K |
| Gross Profit | -530.80K | -992.80K | -603.56K | -112.21K | 486.00 |
| Gross Profit Ratio | -49.24% | -61.98% | -31.07% | -11.36% | 0.06% |
| Research & Development | 370.14K | 593.22K | 1.15M | 634.04K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | -362.91K | -403.79K | -1.15M | -47.03K | 317.49K |
| Other Expenses | 1.64M | 1.78M | 1.13M | 289.00K | 95.81K |
| Operating Expenses | 1.64M | 1.78M | 1.13M | 289.00K | 95.81K |
| Cost & Expenses | 3.25M | 4.38M | 3.67M | 1.39M | 875.97K |
| Interest Income | 572.30K | 463.77K | 300.72K | 37.15K | 4.32K |
| Interest Expense | 24.26K | 30.01K | 26.45K | 24.90K | 7.42K |
| Depreciation & Amortization | 1.06M | 908.65K | 558.29K | 46.40K | 6.48K |
| EBITDA | -517.34K | -1.39M | -860.42K | -317.65K | -84.52K |
| EBITDA Ratio | -47.99% | -88.72% | -45.46% | -32.16% | -10.83% |
| Operating Income | -2.18M | -2.78M | -1.73M | -401.20K | -95.33K |
| Operating Income Ratio | -201.76% | -173.35% | -89.00% | -40.62% | -12.21% |
| Total Other Income/Expenses | 558.64K | 427.04K | 261.09K | 12.25K | -3.10K |
| Income Before Tax | -1.62M | -2.35M | -1.47M | -388.95K | -98.43K |
| Income Before Tax Ratio | -149.94% | -146.69% | -75.56% | -39.38% | -12.61% |
| Income Tax Expense | -45.77K | 13.59K | -126.97K | -490.00 | 507.21 |
| Net Income | -1.57M | -2.36M | -1.34M | -388.46K | -98.93K |
| Net Income Ratio | -145.70% | -147.54% | -69.02% | -39.33% | -12.67% |
| EPS | -0.49 | -0.73 | -0.42 | -0.12 | -0.03 |
| EPS Diluted | -0.49 | -0.73 | -0.42 | -0.12 | -0.03 |
| Weighted Avg Shares Out | 3.23M | 3.22M | 3.22M | 3.22M | 3.22M |
| Weighted Avg Shares Out (Dil) | 3.23M | 3.22M | 3.22M | 3.22M | 3.22M |
Source: https://incomestatements.info
Category: Stock Reports